Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer
- Conditions
- Pancreatic Cancer Non-resectable
- Interventions
- Drug: Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX
- Registration Number
- NCT03941093
- Lead Sponsor
- FibroGen
- Brief Summary
This is a Phase 3, randomized, double-blind trial to evaluate the efficacy and safety of neoadjuvant treatment with pamrevlumab or placebo in combination with either gemcitabine plus nab-paclitaxel (G/NP) or FOLFIRINOX in the treatment of participants with locally advanced, unresectable pancreatic cancer.
- Detailed Description
Participants will be randomized in a 1:1 ratio to one of the two study treatment arms; pamrevlumab with either G/NP or FOLFIRINOX, placebo with G/NP or FOLFIRINOX.
Each participant may receive up to 6 cycles of treatment (each treatment cycle is 28 days). Tumor tissue will be collected during resection to determine surgical outcome and for biomarker analysis. Tumor response will be evaluated by changes in CT scan, FDG-PET, CA 19-9, and NCCN® guidelines.
All participants randomized will have a safety follow-up visit approximately 28 days after the last dose of study treatment and a final safety follow-up phone call at approximately 60 days after the last dose.
Participants who complete study treatment will be evaluated for surgical exploration for possible R0 or R1 resection. Surgery will occur at least 4 weeks after the last dose (allowing for a wash-out period from treatment) and only after receipt of the recommendation from the central review board with regards to surgical eligibility. Surgery will occur no longer than 8 weeks after the last dose. Participants who undergo surgery will be evaluated for surgical complications for at least an additional 90 days following discharge from surgery.
Participants who are ineligible for surgical exploration (i.e. participants who did not complete study treatment or do not meet any of the protocol defined criteria or had a contraindication to surgery) will continue in the Follow-up period and receive treatment as per standard of care (SOC) for each institution.
All participants will be followed for disease progression (if not previously detected) or recurrence following resection (local progression or metastatic disease). Participants will also be followed for any additional anti-cancer therapy received for their pancreatic cancer. All participants will be followed for survival (until death) or until the last participant to complete treatment reaches 18 months post-treatment.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 284
- Understand and sign informed consent; be willing to comply with study procedures, including surgery
- Age ≥ 18 years
- Be a male, or non-pregnant and non-lactating female
- Negative serum B-hCG pregnancy test at screening for women of childbearing potential
- Male participants with partners of childbearing potential and female participants of childbearing potential are required to use highly effective contraception methods during the conduct of the study and for 6 months after the last dose of study drug
- Histologically or cytologically proven diagnosis of pancreatic ductal adenocarcinoma (PDAC)
- Locally advanced pancreatic cancer considered unresectable according to NCCN Guidelines® Version 2.2018 as determined by central imaging
- Measurable disease as defined by RECIST 1.1 criteria as determined by central imaging
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate liver function: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <2.5 x upper limit of normal (ULN), alkaline phosphatase <2.5 x ULN, and bilirubin ≤1.5 x ULN or in participants with biliary stenting ≤2.0 x ULN
- Adequate bone marrow function: platelets >100,000 cells/mm3, hemoglobin >9.0 g/dl and absolute neutrophil count (ANC) >1,500 cells/mm3
- Adequate renal function: creatinine < 1.5 x ULN, creatinine clearance ≥ 30 mL/min
- Less than grade 2 pre-existing peripheral neuropathy (per CTCAE)
- Prior chemotherapy or radiation for pancreatic cancer
- Previous (within the past 3 years) or concurrent malignancy diagnosis except non-melanoma skin cancer and in situ carcinomas (excluding in situ breast cancer)
- Major surgery within 4 weeks prior to signing informed consent form. Biliary stents are permitted.
- History of allergy or hypersensitivity to human, humanized or chimeric monoclonal antibodies
- History of allergy or hypersensitivity to any of the chemotherapy agents being prescribed or their excipients
- Any medical or surgical condition that may place the participant at increased risk while on study
- Any condition potentially decreasing compliance to study procedures
- Exposure to another investigational drug within 28 days of first dosing visit, or 5 half-lives of the investigational drug (whichever is longer)
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active systemic infections, symptomatic congestive heart failure, unstable angina pectoris, clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Documented history of drug or alcohol abuse within 6 months of signing informed consent
- Any medical condition that, in the opinion of the investigator, may pose a safety risk to a participant in this trial, may confound the assessment of safety and efficacy, or may interfere with study participation
- Participants with a history of interstitial pulmonary disease, hepatitis C virus (HCV), hepatitis B virus (HBV) or human immunodeficiency virus (HIV) infection
- Participants who have been administered a live vaccine within 4 weeks prior to the first administration of therapy
- Participants who cannot stop chronic medications that inhibit or induce cytochrome P (CYP) 2C8 or CYP3A4
- Participants with poorly controlled comorbid conditions, including; congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), uncontrolled diabetes mellitus (DM) or neurologic disorders (not acutely related to pancreatic cancer) or limited function
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm A Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX Arm B Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX
- Primary Outcome Measures
Name Time Method Overall Survival Up to approximately 5 years Overall survival was defined as the time from date of randomization to date of death due to any cause. Overall survival was calculated using the Kaplan-Meier method.
- Secondary Outcome Measures
Name Time Method Event-free Survival (EFS) Up to approximately 5 years The EFS endpoint was a composite time-to-event endpoint. The event being analyzed ('treatment failure') was defined as the earliest occurrence of: a) failure to achieve disease-free status locally after completion of neoadjuvant treatment and/or after surgery (that is, resection failure or progression that precludes surgery); b) local or distant recurrence, or c) death. The EFS was calculated using the Kaplan-Meier method.
Progression-free Survival (PFS) as Assessed Using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Up to approximately 5 years The PFS was defined as time from date of randomization until disease progression or death due to any cause, whichever occurred first. PFS was calculated using the Kaplan-Meier method. Progression was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of at least 5 millimeters (mm). Unequivocal progression of existing non-target lesions and the appearance of one or more new lesions was also considered progression.
Number of Participants With Best Overall Objective Response as Assessed Using RECIST v1.1 Up to approximately 5 years Best overall objective response was defined as a complete response (CR) or partial response (PR). CR was defined as disappearance of all target or non-target lesions and normalization of tumor marker level (for non-target lesions), any pathological lymph nodes (whether target or non-target) must have reduced in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Trial Locations
- Locations (90)
Ohio State University
🇺🇸Columbus, Ohio, United States
Baylor College of Medicine
🇺🇸Houston, Texas, United States
National Cancer Center
🇰🇷Goyang-si, Gyeonggi-do, Korea, Republic of
St. Joseph's Hospital and Medical Cancer Center
🇺🇸Phoenix, Arizona, United States
Karmanos Cancer Institute
🇺🇸Detroit, Michigan, United States
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
🇨🇳Shanghai, China
University College London Hospitals NHS Foundation Trust
🇬🇧London, United Kingdom
University of Nebraska Medical Center
🇺🇸Omaha, Nebraska, United States
West Virginia University
🇺🇸Morgantown, West Virginia, United States
Klinikum Wels-Grieskirchen GmbH
🇦🇹Wels, Austria
Medizinische Universität Wien
🇦🇹Wien, Austria
CUB Hôpital Erasme
🇧🇪Brussels, Belgium
The Ottawa Hospital
🇨🇦Ottawa, Ontario, Canada
Sunnybrook Health Sciences Centre
🇨🇦Toronto, Ontario, Canada
Princess Margaret Cancer Centre/University Health Network
🇨🇦Toronto, Ontario, Canada
Peking Union Medical College Hospital
🇨🇳Dongcheng, Beijing, China
McGill University Health Center
🇨🇦Montreal, Quebec, Canada
Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
🇨🇳Wuhan, Hubei, China
Huashan Hospital affiliated with Fudan University
🇨🇳Jing'an, Shanghai, China
West China Hospital of Sichuan University
🇨🇳Chengdu, China
CHRU Jean Minjoz
🇫🇷Besançon Cedex, France
Xinhua Hospital Affiliated to Shanghai Jiaotong University School Of Medicine
🇨🇳Shanghai, China
Hopital BEAUJON
🇫🇷Clichy, France
CHU Estaing
🇫🇷Clermont Ferrand, France
CHU Grenoble Alpes
🇫🇷La Tronche, France
Centre Georges-François Leclerc
🇫🇷Dijon, France
Centre Léon Bérard
🇫🇷Lyon, France
Hôpital Edouard Herriot
🇫🇷Lyon, France
Groupe Hospitalier Pitié Salpêtrière
🇫🇷Paris, France
Haut-Lévêque
🇫🇷Pessac, France
Institut de Cancérologie de l'Ouest Pays de Loire
🇫🇷Saint Herblain Cedex, France
Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie
🇩🇪Berlin, Germany
Technische Universität Dresden, Medizinische Klinik und Poliklinik I
🇩🇪Dresden, Germany
Klinikum rechts der Isar der Technischen Universität München
🇩🇪München, Germany
Klinikum der Universität München, Medizinische Klinik und Poliklinik III
🇩🇪München, Germany
Shamir Medical center Asaf Harofeh
🇮🇱Be'er Ya'aqov, Israel
Hadassah University Hospital Ein Kerem
🇮🇱Jerusalem, Israel
Meir Medical center
🇮🇱Kfar Saba, Israel
Rabin Medical Center
🇮🇱Petach Tikva, Israel
Grande Ospedale Metropolitano Niguarda, Oncologia Medica Falck
🇮🇹Milano, Italy
Istituto Europeo di Oncologia
🇮🇹Milano, Italy
Instituto Scientifico Romagnolog per lo Studio e la Cura dei Tumori
🇮🇹Meldola, Italy
IRCCS Ospedale San Raffaele
🇮🇹Milano, Italy
AOU Federico II
🇮🇹Napoli, Italy
Istituto Clinico Humanitas
🇮🇹Rozzano, Italy
CRC di Verona
🇮🇹Verona, Italy
Seoul National University Budang Hospital
🇰🇷Seongnam-si, Geyonggi-do, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
The Catholic University of Korea, Seoul St. Mary's Hospital
🇰🇷Seoul, Korea, Republic of
Hospital Universitaro Vall D'Hebron
🇪🇸Barcelona, Spain
Hospital de la Santa Creu i Sant Pau
🇪🇸Barcelona, Spain
Institut Catalá d'Oncologia (ICO Girona). Hospital Dr. Josep Trueta
🇪🇸Girona, Spain
Hospital General Universitario Gregorio Marañon
🇪🇸Madrid, Spain
MD Anderson Cancer Center
🇪🇸Madrid, Spain
Hospital Clinico Universitario de Valencia
🇪🇸Valencia, Spain
Hospital Clinico San Carlos
🇪🇸Madrid, Spain
Imperial College Healthcare NHS Trust
🇬🇧London, United Kingdom
UCLA
🇺🇸Los Angeles, California, United States
UC San Diego Moores Cancer Center
🇺🇸La Jolla, California, United States
Elmhurst Memorial Hospital - Nancy W. Knowles Cancer Center
🇺🇸Elmhurst, Illinois, United States
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
🇺🇸Indianapolis, Indiana, United States
University of Kansas Hospital
🇺🇸Westwood, Kansas, United States
Maine Health Cancer Care
🇺🇸South Portland, Maine, United States
University of Massachusetts
🇺🇸Worcester, Massachusetts, United States
NYU Langone Health
🇺🇸New York, New York, United States
University of Cincinnati Medical Center
🇺🇸Cincinnati, Ohio, United States
SUNY Upstate Medical University
🇺🇸Syracuse, New York, United States
Allegheny General Hospital
🇺🇸Pittsburgh, Pennsylvania, United States
Reading Hospital McGlinn Cancer Institute
🇺🇸West Reading, Pennsylvania, United States
Stony Brook University
🇺🇸Stony Brook, New York, United States
Baylor Scott & White Medical Center
🇺🇸Temple, Texas, United States
Renovatio Clinic
🇺🇸The Woodlands, Texas, United States
Inova Schar Cancer Institute
🇺🇸Fairfax, Virginia, United States
Virginia Mason Medical Center
🇺🇸Seattle, Washington, United States
University of Washington Medical Center
🇺🇸Seattle, Washington, United States
The First Affiliated Hospital Of Xi'an Jiaotong University
🇨🇳Xi'an, Shaanxi, China
Severance Hospital, Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
Hospital Universitario Miguel Servet
🇪🇸Zaragoza, Spain
New Mexico Cancer Care Alliance
🇺🇸Albuquerque, New Mexico, United States
Chonnam National University Hwasun Hospital
🇰🇷Hwasun, Jeollanam-do, Korea, Republic of
UC Davis Comprehensive Cancer Center
🇺🇸Sacramento, California, United States
Edward Cancer Center
🇺🇸Naperville, Illinois, United States
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
Yale New Haven Hospital
🇺🇸New Haven, Connecticut, United States
Norton Cancer Institute, Audubon Hospital Campus
🇺🇸Louisville, Kentucky, United States
University of Michigan
🇺🇸Ann Arbor, Michigan, United States
Saint Luke's Hospital
🇺🇸Kansas City, Missouri, United States
Alvaro Cunqueiro Hospital
🇪🇸Vigo, Pontevedra, Spain
Thomas Jefferson University
🇺🇸Philadelphia, Pennsylvania, United States
Jiangsu Province Hospital
🇨🇳Nanjing, China